Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herbalife acquisition

This article was originally published in The Tan Sheet

Executive Summary

Direct marketer cancels Euro tranche of high-yield bond due to lack of demand in Europe, company says. Proceeds were to be used toward financing of going-private transaction, which is still expected to close this summer. Firm previously planned to use up to $238 mil. in net proceeds from issuance of senior subordinated notes offered in Euro, U.S. dollar-denominated tranches (1"The Tan Sheet" June 17, 2002, p. 5). In revised filing with SEC June 27, Herbalife now says it will contribute approximately $213.9 mil. in available cash toward the acquisition. Financing also will include $162.9 mil. in proceeds from senior subordinated notes, up to $24.8 mil. from senior notes. Acquiring companies Whitney, Golden Gate now expected to provide equity financing of $176 mil., although amount could increase to $220.3 mil...

You may also be interested in...

Herbalife Ephedrine Alkaloid Supplements Slated For Discontinuation

Herbalife is getting out of the ephedra supplement business

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts